Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

C. E. Jackson; R. J. Barohn; G. Gronseth; S. Pandya; L. Herbelin; Rabi Tawil; Robert Griggs; Charles Thornton; John Kissel; Jerry Mendell; Angela Genge; George Karpati; Carlayne Jackson; Michael Rose; Anthony Amato; Richard Barohn; David Saperstein; Michael P. McDermott; Shree Pandya; Deborah Wahlen; Wendy King; Adriana Venturini; Deborah Myers; Samantha Prisley; Michelle Tagerman; Meredith O'Brien; Laura Herbelin; Lynn Cos; Karen Downing; Roza Plesiak; Frieda Barefield; Catherine Morrison; Hannah Briemberg; Robert Holloway; Derick Peterson; Joanne Janciuras; William Martens; Christine Blood

doi:10.1002/mus.20958

Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

C. E. Jackson, R. J. Barohn, G. Gronseth, S. Pandya, L. Herbelin, Rabi Tawil, Robert Griggs, Charles Thornton, John Kissel, Jerry Mendell, Angela Genge, George Karpati, Carlayne Jackson, Michael Rose, Anthony Amato, Richard Barohn, David Saperstein, Michael P. McDermott, Shree Pandya, Deborah WahlenWendy King, Adriana Venturini, Deborah Myers, Samantha Prisley, Michelle Tagerman, Meredith O'Brien, Laura Herbelin, Lynn Cos, Karen Downing, Roza Plesiak, Frieda Barefield, Catherine Morrison, Hannah Briemberg, Robert Holloway, Derick Peterson, Joanne Janciuras, William Martens, Christine Blood

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Abstract

We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.

Original language	English (US)
Pages (from-to)	473-476
Number of pages	4
Journal	Muscle and Nerve
Volume	37
Issue number	4
DOIs	https://doi.org/10.1002/mus.20958
State	Published - Apr 2008

Keywords

Beta-interferon
Functional scale
Inclusion-body myositis
Outcome measure
Quality of life

ASJC Scopus subject areas

Physiology
Clinical Neurology
Cellular and Molecular Neuroscience
Physiology (medical)

Access to Document

10.1002/mus.20958

Cite this

Jackson, C. E., Barohn, R. J., Gronseth, G., Pandya, S., Herbelin, L., Tawil, R., Griggs, R., Thornton, C., Kissel, J., Mendell, J., Genge, A., Karpati, G., Jackson, C., Rose, M., Amato, A., Barohn, R., Saperstein, D., McDermott, M. P., Pandya, S., ... Blood, C. (2008). Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity. Muscle and Nerve, 37(4), 473-476. https://doi.org/10.1002/mus.20958

Jackson, CE, Barohn, RJ, Gronseth, G, Pandya, S, Herbelin, L, Tawil, R, Griggs, R, Thornton, C, Kissel, J, Mendell, J, Genge, A, Karpati, G, Jackson, C, Rose, M, Amato, A, Barohn, R, Saperstein, D, McDermott, MP, Pandya, S, Wahlen, D, King, W, Venturini, A, Myers, D, Prisley, S, Tagerman, M, O'Brien, M, Herbelin, L, Cos, L, Downing, K, Plesiak, R, Barefield, F, Morrison, C, Briemberg, H, Holloway, R, Peterson, D, Janciuras, J, Martens, W & Blood, C 2008, 'Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity', Muscle and Nerve, vol. 37, no. 4, pp. 473-476. https://doi.org/10.1002/mus.20958

@article{5858c19518b9400882a6592e9f672c6b,

title = "Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity",

abstract = "We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.",

keywords = "Beta-interferon, Functional scale, Inclusion-body myositis, Outcome measure, Quality of life",

author = "Jackson, {C. E.} and Barohn, {R. J.} and G. Gronseth and S. Pandya and L. Herbelin and Rabi Tawil and Robert Griggs and Charles Thornton and John Kissel and Jerry Mendell and Angela Genge and George Karpati and Carlayne Jackson and Michael Rose and Anthony Amato and Richard Barohn and David Saperstein and McDermott, {Michael P.} and Shree Pandya and Deborah Wahlen and Wendy King and Adriana Venturini and Deborah Myers and Samantha Prisley and Michelle Tagerman and Meredith O'Brien and Laura Herbelin and Lynn Cos and Karen Downing and Roza Plesiak and Frieda Barefield and Catherine Morrison and Hannah Briemberg and Robert Holloway and Derick Peterson and Joanne Janciuras and William Martens and Christine Blood",

year = "2008",

month = apr,

doi = "10.1002/mus.20958",

language = "English (US)",

volume = "37",

pages = "473--476",

journal = "Muscle and Nerve",

issn = "0148-639X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Inclusion body myositis functional rating scale

T2 - A reliable and valid measure of disease severity

AU - Jackson, C. E.

AU - Barohn, R. J.

AU - Gronseth, G.

AU - Pandya, S.

AU - Herbelin, L.

AU - Tawil, Rabi

AU - Griggs, Robert

AU - Thornton, Charles

AU - Kissel, John

AU - Mendell, Jerry

AU - Genge, Angela

AU - Karpati, George

AU - Jackson, Carlayne

AU - Rose, Michael

AU - Amato, Anthony

AU - Barohn, Richard

AU - Saperstein, David

AU - McDermott, Michael P.

AU - Pandya, Shree

AU - Wahlen, Deborah

AU - King, Wendy

AU - Venturini, Adriana

AU - Myers, Deborah

AU - Prisley, Samantha

AU - Tagerman, Michelle

AU - O'Brien, Meredith

AU - Herbelin, Laura

AU - Cos, Lynn

AU - Downing, Karen

AU - Plesiak, Roza

AU - Barefield, Frieda

AU - Morrison, Catherine

AU - Briemberg, Hannah

AU - Holloway, Robert

AU - Peterson, Derick

AU - Janciuras, Joanne

AU - Martens, William

AU - Blood, Christine

PY - 2008/4

Y1 - 2008/4

N2 - We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.

AB - We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.

KW - Beta-interferon

KW - Functional scale

KW - Inclusion-body myositis

KW - Outcome measure

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=41849098898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849098898&partnerID=8YFLogxK

U2 - 10.1002/mus.20958

DO - 10.1002/mus.20958

M3 - Article

C2 - 18236463

AN - SCOPUS:41849098898

VL - 37

SP - 473

EP - 476

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 4

ER -

Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this